search
Back to results

Phase I Clinical Study of GC012F Injection in Treatment of Refractory Systemic Lupus Erythematosus

Primary Purpose

CAR-T

Status
Recruiting
Phase
Phase 1
Locations
China
Study Type
Interventional
Intervention
GC012F injection
Sponsored by
Zhejiang University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for CAR-T

Eligibility Criteria

18 Years - 70 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: 18-70 years old; Total score ≥ 10 on the EULAR/ACR 2019 SLE classification criteria; SELENA-SLEDAI≥8; Patients with CD19+ B-cell; Active organ involvement; Hemoglobin≥85 g/L; WBC≥2.5×10^9/L NEUT≥1×10^9/L; PLT≥50×10^9/L; AST/ALT below 2 times the upper limit of normal; Creatinine clearance ≥30 mL/min; blood bilirubin ≤2.0 mg/dl; echocardiography indicates that the ejection fraction is ≥50%; Adequate venous access for apheresis, and no other contraindications for leukapheresis; Women of childbearing age should have a negative serum or urine pregnancy test at screening and baseline. Subjects agree to take effective contraceptive measures during the trial until at least 1 year after CAR-T cells infusion. Agree to attend follow-up visits as required; Voluntary participation and informed consent signed by the patient or his/her legal/authorized representative; Exclusion Criteria: Renal disease: severe lupus nephritis (serum creatinine > 2.5 mg/dL or 221 μmol/L) within 8 weeks prior to leukapheresis, or subjects who need prohibited drugs to treat active nephritis or subjects who need hemodialysis; CNS disease: including epilepsy, psychosis, organic encephalopathy syndrome, cerebrovascular accident [CVA], encephalitis or CNS vasculitis, psychiatric patients with depression or suicidal thoughts; Patients with serious lesions and history of present illness of vital organs such as heart, liver, kidney and blood and endocrine system; Patients with immunodeficiency, uncontrolled active infections and active or recurrent peptic ulcers; Received immunosuppressive therapy within 1 week prior to leukapheresis; Patients with HIV infection; Active infection of hepatitis B virus or hepatitis C virus; Patients with syphilis infection; The presence or suspicion of an active fungal, bacterial, viral or other infection that cannot be controlled during screening; Received live vaccine treatment within 4 weeks prior to screening; Severe allergies or hypersensitivity; Contraindication to cyclophosphamide in combination with fludarabine; Subjects who have undergone major surgery within 2 weeks prior to signing the informed consent form, or who are scheduled to have surgery (other than local anesthetic surgery) during the trial or within 2 weeks of the infusion; cannula or drainage tubes other than central venous catheters; Pregnant or lactating women, or subjects who plan to have children within 1 year of treatment; Subjects with prior CD19 or BCMA-targeted therapy Participated in any clinical study within 3 months prior to enrollment Any situations that the investigator believes the patients are not suitable for the study.

Sites / Locations

  • The First Affiliated Hospital,College of Medicine, Zhejiang UniversityRecruiting

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

GC012F injection (CD19-BCMA CAR-T cells)

Arm Description

Dose level: DL1:1±20%×10^5/kg, DL2:2±20%×10^5/kg DL3:3±20%×10^5/kg

Outcomes

Primary Outcome Measures

The proportion of subjects with DLT
DLT definition is dose-limiting toxicity
The proportion of subjects with adverse events
All adverse events were evaluated according to NCI-CTCAE v5.0 criteria

Secondary Outcome Measures

Proportion of subjects achieving SRI-4
SELEAN-SLEDAI,BILAG,PGA
Number of CAR-T cells and CAR gene copies in subjects'blood and bone marrow (if applicable)
Test method: flow cytometry and qPCR

Full Information

First Posted
April 26, 2023
Last Updated
May 10, 2023
Sponsor
Zhejiang University
Collaborators
Gracell Biotechnology Shanghai Co., Ltd.
search

1. Study Identification

Unique Protocol Identification Number
NCT05846347
Brief Title
Phase I Clinical Study of GC012F Injection in Treatment of Refractory Systemic Lupus Erythematosus
Official Title
Phase I Clinical Study of GC012F Injection in Treatment of Refractory Systemic Lupus Erythematosus
Study Type
Interventional

2. Study Status

Record Verification Date
May 2023
Overall Recruitment Status
Recruiting
Study Start Date
May 15, 2023 (Anticipated)
Primary Completion Date
October 19, 2023 (Anticipated)
Study Completion Date
April 19, 2025 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Zhejiang University
Collaborators
Gracell Biotechnology Shanghai Co., Ltd.

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
This is a phase I, single arm, non-randomized, open label, treatment study trial to determine the recommended phase II dose of GC012F injection (CD19-BCMA CAR-T cells) in patients with refractory systemic lupus erythematosus.
Detailed Description
Systemic lupus erythematosus (SLE) is a kind of autoimmune diseases mediated by autoantibody-forming immune complexes, which involving multiple systems and organs. Autoreactive B cells can self-activate and differentiate into plasma cells releasing large amounts of autoantibodies, while they can also present their own antigens to autoimmune T cells, thus activating T cells and promoting the release of inflammatory factors. Traditional SLE treatment aims at long-term remission, while, CD19- BCMA CAR-T cells can theoretically completely deplete abnormal antibody-producing B cells, allowing immune rebuilding and restoring the patient's normal immune function, achieving drug-free survival, which fully reflects the application prospects of CAR-T therapy in SLE.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
CAR-T

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
15 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
GC012F injection (CD19-BCMA CAR-T cells)
Arm Type
Experimental
Arm Description
Dose level: DL1:1±20%×10^5/kg, DL2:2±20%×10^5/kg DL3:3±20%×10^5/kg
Intervention Type
Drug
Intervention Name(s)
GC012F injection
Other Intervention Name(s)
CD19-BCMA CAR-T cells
Intervention Description
Each subject will receive GC012F injection (CD19-BCMA CAR-T cells) once by intravenous infusion on Day 0.
Primary Outcome Measure Information:
Title
The proportion of subjects with DLT
Description
DLT definition is dose-limiting toxicity
Time Frame
Within 28 days after GC012F injection infusion
Title
The proportion of subjects with adverse events
Description
All adverse events were evaluated according to NCI-CTCAE v5.0 criteria
Time Frame
Within 12 weeks after GC012F injection infusion
Secondary Outcome Measure Information:
Title
Proportion of subjects achieving SRI-4
Description
SELEAN-SLEDAI,BILAG,PGA
Time Frame
4, 8, 12 and 24 weeks after GC012F injection infusion
Title
Number of CAR-T cells and CAR gene copies in subjects'blood and bone marrow (if applicable)
Description
Test method: flow cytometry and qPCR
Time Frame
After GC012F injection infusion [day 4, 7, 10, 14 and week 4, 8, 12, 24]

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: 18-70 years old; Total score ≥ 10 on the EULAR/ACR 2019 SLE classification criteria; SELENA-SLEDAI≥8; Patients with CD19+ B-cell; Active organ involvement; Hemoglobin≥85 g/L; WBC≥2.5×10^9/L NEUT≥1×10^9/L; PLT≥50×10^9/L; AST/ALT below 2 times the upper limit of normal; Creatinine clearance ≥30 mL/min; blood bilirubin ≤2.0 mg/dl; echocardiography indicates that the ejection fraction is ≥50%; Adequate venous access for apheresis, and no other contraindications for leukapheresis; Women of childbearing age should have a negative serum or urine pregnancy test at screening and baseline. Subjects agree to take effective contraceptive measures during the trial until at least 1 year after CAR-T cells infusion. Agree to attend follow-up visits as required; Voluntary participation and informed consent signed by the patient or his/her legal/authorized representative; Exclusion Criteria: Renal disease: severe lupus nephritis (serum creatinine > 2.5 mg/dL or 221 μmol/L) within 8 weeks prior to leukapheresis, or subjects who need prohibited drugs to treat active nephritis or subjects who need hemodialysis; CNS disease: including epilepsy, psychosis, organic encephalopathy syndrome, cerebrovascular accident [CVA], encephalitis or CNS vasculitis, psychiatric patients with depression or suicidal thoughts; Patients with serious lesions and history of present illness of vital organs such as heart, liver, kidney and blood and endocrine system; Patients with immunodeficiency, uncontrolled active infections and active or recurrent peptic ulcers; Received immunosuppressive therapy within 1 week prior to leukapheresis; Patients with HIV infection; Active infection of hepatitis B virus or hepatitis C virus; Patients with syphilis infection; The presence or suspicion of an active fungal, bacterial, viral or other infection that cannot be controlled during screening; Received live vaccine treatment within 4 weeks prior to screening; Severe allergies or hypersensitivity; Contraindication to cyclophosphamide in combination with fludarabine; Subjects who have undergone major surgery within 2 weeks prior to signing the informed consent form, or who are scheduled to have surgery (other than local anesthetic surgery) during the trial or within 2 weeks of the infusion; cannula or drainage tubes other than central venous catheters; Pregnant or lactating women, or subjects who plan to have children within 1 year of treatment; Subjects with prior CD19 or BCMA-targeted therapy Participated in any clinical study within 3 months prior to enrollment Any situations that the investigator believes the patients are not suitable for the study.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
He Huang, PhD
Phone
86-13605714822
Email
hehuangyu@126.com
First Name & Middle Initial & Last Name or Official Title & Degree
Yongxian Hu, MD
Phone
+8615957162012
Email
huyongxian2000@aliyun.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
He Huang
Organizational Affiliation
Zhejiang University
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Zhihong Liu
Organizational Affiliation
Zhejiang university school of medicine
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Jin Lin
Organizational Affiliation
Zhejiang University
Official's Role
Principal Investigator
Facility Information:
Facility Name
The First Affiliated Hospital,College of Medicine, Zhejiang University
City
Hangzhou
State/Province
Zhejiang
ZIP/Postal Code
310003
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
He Huang, PhD
Phone
86-13605714822
Email
hehuangyu@126.com
First Name & Middle Initial & Last Name & Degree
Yongxian Hu, PhD
Phone
86-15957162012
Email
huyongxian2000@aliyun.com

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Phase I Clinical Study of GC012F Injection in Treatment of Refractory Systemic Lupus Erythematosus

We'll reach out to this number within 24 hrs